Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07802132 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia

StatusNot Yet Recruiting
PhaseNot specified
Started2026-09-20
View on ClinicalTrials.gov ↗
This study is a prospective, observational, single-arm, open-label, multicenter, real-world study conducted in Chinese adult participants with schizophrenia who meet the International Classification of Diseases (ICD)-10 diagnostic criteria. The total study duration is up to 17 weeks, including a screening/baseline data collection period followed by an observational part during which KarXT treatmentpattern, schizophrenia treatment decisions and compliance will be observed in the real-world setting.
Trial Details
NCT Number NCT07802132
Lead Sponsor Zai Lab (Shanghai) Co., Ltd.
Conditions Schizophrenia Disorder
Enrollment 250 participants
Start Date 2026-09-20
Primary Completion 2027-08-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-03